Target 2035 – an update on private sector contributions-Reference-Cited by-同舟云学术

Target 2035 – an update on private sector contributions

Published:2023 Issue:6 Volume:14 Page:1002-1011
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Ackloo Suzanne¹^ORCID,Antolin Albert A.²^ORCID,Bartolome Jose Manuel³^ORCID,Beck Hartmut⁴^ORCID,Bullock Alex⁵^ORCID,Betz Ulrich A. K.⁶,Böttcher Jark⁷^ORCID,Brown Peter J.⁸^ORCID,Chaturvedi Menorca⁹^ORCID,Crisp Alisa¹⁰,Daniels Danette¹¹^ORCID,Dreher Jan⁴^ORCID,Edfeldt Kristina¹²^ORCID,Edwards Aled M.¹^ORCID,Egner Ursula¹³,Elkins Jon⁵,Fischer Christian¹⁴,Glendorf Tine¹⁵^ORCID,Goldberg Steven¹⁶,Hartung Ingo V.¹⁷^ORCID,Hillisch Alexander⁴^ORCID,Homan Evert¹⁸^ORCID,Knapp Stefan¹⁹²⁰^ORCID,Köster Markus⁹,Krämer Oliver⁹^ORCID,Llaveria Josep³^ORCID,Lessel Uta²¹,Lindemann Sven⁶^ORCID,Linderoth Lars¹⁵,Matsui Hisanori²²^ORCID,Michel Maurice¹⁸,Montel Florian²¹,Mueller-Fahrnow Anke¹³^ORCID,Müller Susanne¹⁹²⁰^ORCID,Owen Dafydd R.²³^ORCID,Saikatendu Kumar Singh²⁴^ORCID,Santhakumar Vijayaratnam¹^ORCID,Sanderson Wendy²⁵,Scholten Cora²⁶,Schapira Matthieu¹²⁷^ORCID,Sharma Sujata¹⁶,Shireman Brock¹⁶^ORCID,Sundström Michael¹²,Todd Matthew H.²⁸^ORCID,Tredup Claudia¹⁹²⁰,Venable Jennifer¹⁶,Willson Timothy M.²⁹^ORCID,Arrowsmith Cheryl H.¹³⁰^ORCID

Affiliation:

1. Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada

2. ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain

3. A Division of Janssen-Cilag S.A., Janssen Research and Development, Toledo, Spain

4. Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany

5. Center for Medicines Discovery, Old Road Campus, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK

6. Merck KGaA, Darmstadt, Germany

7. Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria

8. Structural Genomics Consortium, University of North Carolina at Chapel Hill, USA

9. Boehringer Ingelheim International, Binger Str. 173, D-55216 Ingelheim, Germany

10. Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK

11. Foghorn Therapeutics, 500 Technology Square, Suite 700, Cambridge, MA 02139, USA

12. Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

13. Nuvisan Innovation Campus Berlin GmbH, Müllerstraße 178, 13353, Berlin, Germany

14. Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, USA

15. Research & Early Development, Novo Nordisk A/S, Måløv, Denmark

16. Janssen Research and Development LLC, San Diego, California, USA

17. Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany

18. Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

19. Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany

20. Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Frankfurt 60438, Germany

21. Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany

22. Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

23. Discovery Network Group, Pfizer Medicine Design, Cambridge, MA 02139, USA

24. Global Research Externalization, Takeda California, Inc., 9625 Towne Center Drive, San Diego, CA 92121, USA

25. Janssen Research & Development, Janssen Pharmaceutica N. V, Beerse, Belgium

26. Research and Development, Bayer AG, Pharmaceuticals, 13353 Berlin, Germany

27. Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada

28. School of Pharmacy, University College London, London, WC1N 1AX, UK

29. Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

30. Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1L7, Canada

Abstract

Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.

Funder

Eshelman Institute for Innovation, University of North Carolina

Pfizer

Janssen Research and Development

Boehringer Ingelheim

Ontario Genomics Institute

European Federation of Pharmaceutical Industries and Associations

Ontario Institute for Cancer Research

Genentech

Takeda Pharmaceutical Company

Merck KGaA

Kungliga Tekniska Högskolan